FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200113990> ?p ?o ?g. }

• W4200113990 endingPage "100794" @default.
• W4200113990 startingPage "100794" @default.
• W4200113990 abstract "The COVID-19 pandemic is one of the greatest threats to human health in the 21st century with more than 257 million cases and over 5.17 million deaths reported worldwide (as of November 23, 2021. Various agents were initially proclaimed to be effective against SARS-CoV-2, the etiological agent of COVID-19. Hydroxychloroquine, lopinavir/ritonavir, and ribavirin are all examples of therapeutic agents, whose efficacy against COVID-19 was later disproved. Meanwhile, concentrated efforts of researchers and clinicians worldwide have led to the identification of novel therapeutic options to control the disease including PAXLOVID™ (PF-07321332). Although COVID-19 cases are currently treated using a comprehensive approach of anticoagulants, oxygen, and antibiotics, the novel Pfizer agent PAXLOVID™ (PF-07321332), an investigational COVID-19 oral antiviral candidate, significantly reduced hospitalization time and death rates, based on an interim analysis of the phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness. The scheduled interim analysis demonstrated an 89 % reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset (primary endpoint). However, there still exists a great need for the development of additional treatments, as the recommended therapeutic options are insufficient in many cases. Thus far, mRNA and vector vaccines appear to be the most effective modalities to control the pandemic. In the current review, we provide an update on the progress that has been made since April 2020 in clinical trials concerning the effectiveness of therapies available to combat COVID-19. We focus on currently recommended therapeutic agents, including steroids, various monoclonal antibodies, remdesivir, baricitinib, anticoagulants and PAXLOVID™ summarizing the latest original studies and meta-analyses. Moreover, we aim to discuss other currently and previously studied agents targeting COVID-19 that either show no or only limited therapeutic activity. The results of recent studies report that hydroxychloroquine and convalescent plasma demonstrate no efficacy against SARS-CoV-2 infection. Lastly, we summarize the studies on various drugs with incoherent or insufficient data concerning their effectiveness, such as amantadine, ivermectin, or niclosamide." @default.
• W4200113990 created "2021-12-31" @default.
• W4200113990 creator A5002321383 @default.
• W4200113990 creator A5015174059 @default.
• W4200113990 creator A5021724266 @default.
• W4200113990 creator A5040443846 @default.
• W4200113990 creator A5048341944 @default.
• W4200113990 creator A5056911678 @default.
• W4200113990 creator A5059244618 @default.
• W4200113990 creator A5067647094 @default.
• W4200113990 creator A5078367437 @default.
• W4200113990 creator A5086731030 @default.
• W4200113990 date "2021-12-01" @default.
• W4200113990 modified "2023-10-18" @default.
• W4200113990 title "An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment" @default.
• W4200113990 cites W1153335416 @default.
• W4200113990 cites W1480121036 @default.
• W4200113990 cites W1965936780 @default.
• W4200113990 cites W1974356658 @default.
• W4200113990 cites W2022584773 @default.
• W4200113990 cites W2037845029 @default.
• W4200113990 cites W2039689649 @default.
• W4200113990 cites W2046153984 @default.
• W4200113990 cites W2063092589 @default.
• W4200113990 cites W2065360219 @default.
• W4200113990 cites W2069189810 @default.
• W4200113990 cites W2095522674 @default.
• W4200113990 cites W2104930292 @default.
• W4200113990 cites W2123334163 @default.
• W4200113990 cites W2137836062 @default.
• W4200113990 cites W2151987671 @default.
• W4200113990 cites W2156333187 @default.
• W4200113990 cites W2460946499 @default.
• W4200113990 cites W2489412617 @default.
• W4200113990 cites W2510966473 @default.
• W4200113990 cites W2539536988 @default.
• W4200113990 cites W2560240742 @default.
• W4200113990 cites W2613681538 @default.
• W4200113990 cites W2768032770 @default.
• W4200113990 cites W2794832255 @default.
• W4200113990 cites W2807805342 @default.
• W4200113990 cites W2883231068 @default.
• W4200113990 cites W2886095503 @default.
• W4200113990 cites W2903899730 @default.
• W4200113990 cites W2939482774 @default.
• W4200113990 cites W2942615395 @default.
• W4200113990 cites W2948824749 @default.
• W4200113990 cites W2980655992 @default.
• W4200113990 cites W3001118548 @default.
• W4200113990 cites W3004517278 @default.
• W4200113990 cites W3012379316 @default.
• W4200113990 cites W3012605527 @default.
• W4200113990 cites W3015438945 @default.
• W4200113990 cites W3019235900 @default.
• W4200113990 cites W3020561822 @default.
• W4200113990 cites W3020788415 @default.
• W4200113990 cites W3022373008 @default.
• W4200113990 cites W3025795175 @default.
• W4200113990 cites W3026564616 @default.
• W4200113990 cites W3027630905 @default.
• W4200113990 cites W3029848232 @default.
• W4200113990 cites W3031922646 @default.
• W4200113990 cites W3032677067 @default.
• W4200113990 cites W3034537684 @default.
• W4200113990 cites W3035860713 @default.
• W4200113990 cites W3035947417 @default.
• W4200113990 cites W3036124869 @default.
• W4200113990 cites W3036341863 @default.
• W4200113990 cites W3036343558 @default.
• W4200113990 cites W3036451042 @default.
• W4200113990 cites W3036683212 @default.
• W4200113990 cites W3041886785 @default.
• W4200113990 cites W3042832159 @default.
• W4200113990 cites W3043399375 @default.
• W4200113990 cites W3046480983 @default.
• W4200113990 cites W3048618358 @default.
• W4200113990 cites W3048853848 @default.
• W4200113990 cites W3049574869 @default.
• W4200113990 cites W3080102688 @default.
• W4200113990 cites W3080200258 @default.
• W4200113990 cites W3080704959 @default.
• W4200113990 cites W3080718665 @default.
• W4200113990 cites W3083971467 @default.
• W4200113990 cites W3084552665 @default.
• W4200113990 cites W3086286620 @default.
• W4200113990 cites W3086471698 @default.
• W4200113990 cites W3087084553 @default.
• W4200113990 cites W3087412931 @default.
• W4200113990 cites W3089167370 @default.
• W4200113990 cites W3091759688 @default.
• W4200113990 cites W3091843962 @default.
• W4200113990 cites W3092777173 @default.
• W4200113990 cites W3092888321 @default.
• W4200113990 cites W3092946512 @default.
• W4200113990 cites W3093588691 @default.
• W4200113990 cites W3093644180 @default.
• W4200113990 cites W3094056161 @default.
• W4200113990 cites W3095368098 @default.

• next